((3-亚甲基环丁氧基)甲基)苯 | 1057641-73-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: ((3-亚甲基环丁氧基)甲基)苯
• 英文名称: ((3-methylenecyclobutoxy)methyl)benzene
• 英文别名: Benzene, [[(3-methylenecyclobutyl)oxy]methyl]-；(3-methylidenecyclobutyl)oxymethylbenzene
• CAS: 1057641-73-2
• 化学式: C₁₂H₁₄O
• 分子量: 174.243
• InChiKey: UEGQHXFPWDNFGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  ((3-亚甲基环丁氧基)甲基)苯 在 盐酸 、 N-碘代丁二酰亚胺 、 氢气 、 palladium(II) hydroxide 、 sodium hydride 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 、 乙腈 、 mineral oil 为溶剂， 50.0 ℃ 、344.75 kPa 条件下， 反应 91.0h， 生成
  参考文献：
  名称：

  PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

  摘要：

  本文披露了一系列吡啶吡嘧啶化合物及其在制备与mTORC 1/2双复合物抑制剂相关的药物中的用途，具体披露了将所述化合物，其互变异构体或其药学上可接受的盐如公式（IV）所示用于制备与mTORC 1/2双复合物抑制剂相关的药物。

  公开号：

  US20200339568A1
• 作为产物：
  描述：

  (3-(苄氧基)环丁基)甲基甲磺酸酯 在 potassium tert-butylate 、 sodium iodide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 42.0h， 生成 ((3-亚甲基环丁氧基)甲基)苯
  参考文献：
  名称：

  具有挑战性的 6 官能化 1-oxaspiro[3.3] 庚烷的合成——用于药物发现的新支架

  摘要：

  描述了 1-oxaspiro[3.3] 庚烷家族的七个新构建块的十克级合成。这种通用方法需要 6 到 13 个简单的操作步骤，从市售且廉价的 3-oxocyclobutane-1-carboxylic acid 开始。方便的合成路线可以直接访问这些新模块。最后，使用 LLAMA 软件生成的虚拟组合库表明，此处描述的构建基块展示了填充类铅化学空间的高倾向性。就像传递信件的鸽子一样，新的 1-oxaspiro[3.3] 庚烷家族支架可以将其功能传递给预计在药物发现和设计中具有重要意义的类药化合物。

  DOI：

  10.1016/j.tetlet.2023.154515

文献信息

• [EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019005588A1

  公开（公告）日：2019-01-03

  The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及吡唑并[4,3-b]吡啶化合物，其为M4毒蕈碱型乙酰胆碱受体的变构调节剂。本发明还涉及在可能治疗或预防神经和精神障碍以及涉及M4毒蕈碱型乙酰胆碱受体的疾病中使用所述化合物。本发明还涉及包含这些化合物的组合物。本发明还涉及在可能预防或治疗涉及M4毒蕈碱型乙酰胆碱受体的疾病中使用这些组合物。
• NHC/Nickel(II)‐Catalyzed [3+2] Cross‐Dimerization of Unactivated Olefins and Methylenecyclopropanes
  作者：Jian‐Qiang Huang、Chun‐Yu Ho

  DOI：10.1002/anie.201914542

  日期：2020.3.23

  typical hydroalkenylation reactivity was observed for the first time by using a [NHC-Ni(allyl)]BArF catalyst (NHC=N-heterocyclic carbene). Results show that the C-C cleavage of 1 did not involve a Ni0 oxidative addition, which was crucial in former systems. Thus the method reported here emerges as a complementary method for attaining highly chemo- and regioselective synthesis of methylenecyclopentanes

  通过使用[NHC-Ni（烯丙基）] BArF催化剂（NHC = N-杂环卡宾）首次观察到具有典型的加氢烯基化反应活性的亚甲基环丙烷（1）和未活化的烯烃（2）的交叉二聚。结果表明，CC裂解1不涉及Ni0氧化加成，这在以前的系统中至关重要。因此，这里报道的方法作为获得高度化学和区域选择性的亚甲基环戊烷（3）的广泛方法的补充方法而出现。1在NHC / NiII催化下的有效重排导致2的存在下3的收敛合成。
• Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors
  申请人：Rudra Sonali

  公开号：US08420666B2

  公开（公告）日：2013-04-16

  The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided.

  本发明涉及磷酸二酯酶（PDE）类型4、磷酸二酯酶（PDE）类型7和双重PDE类型4/PDE类型7抑制剂。本文所披露的结构为式1的化合物可用于治疗、预防、抑制或抑制中枢神经系统疾病，例如多发性硬化症；各种影响免疫系统的病理条件，包括艾滋病、移植排斥、自身免疫性疾病如T细胞相关疾病，例如类风湿性关节炎；炎症性疾病，如呼吸道炎症性疾病，包括慢性阻塞性肺疾病（COPD）、哮喘、支气管炎、过敏性鼻炎、成人呼吸窘迫综合症（ARDS）以及其他炎症性疾病，包括但不限于银屑病、休克、特应性皮炎、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎；胃肠道炎症性疾病，如克罗恩病、结肠炎、胰腺炎以及不同类型的癌症，包括白血病；特别适用于人类。本文还提供了所披露的化合物的制备方法、含有所披露的化合物的制药组合物以及它们作为PDE类型4、PDE类型7和双重PDE类型4/PDE类型7抑制剂的用途。
• PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  申请人：Rudra Sonali

  公开号：US20100292196A1

  公开（公告）日：2010-11-18

  The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided.

  本发明涉及磷酸二酯酶（PDE）类型4、磷酸二酯酶（PDE）类型7和双重PDE类型4/PDE类型7抑制剂。本文所披露的具有公式1结构的化合物可以用于治疗、预防、抑制或抑制中枢神经系统疾病，例如多发性硬化症；各种影响免疫系统的病理条件，包括艾滋病、移植排斥、自身免疫性疾病（例如T细胞相关疾病，例如类风湿性关节炎）；炎症性疾病，例如呼吸道炎症性疾病，包括慢性阻塞性肺疾病（COPD）、哮喘、支气管炎、过敏性鼻炎、成人呼吸窘迫综合症（ARDS）以及其他炎症性疾病，包括但不限于牛皮癣、休克、特应性皮炎、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎；胃肠道炎症性疾病，如克罗恩病、结肠炎、胰腺炎以及不同类型的癌症，包括白血病；特别是在人类中。提供了所披露的化合物的制备过程、含有所披露的化合物的药物组合物以及它们作为PDE类型4、PDE类型7和双重PDE类型4/PDE类型7抑制剂的用途。
• 1‐Azaspiro[3.3]heptane as a Bioisostere of Piperidine**
  作者：Alexander A. Kirichok、Hennadii Tkachuk、Yevhenii Kozyriev、Oleh Shablykin、Oleksandr Datsenko、Dmitry Granat、Tetyana Yegorova、Yuliya P. Bas、Vitalii Semirenko、Iryna Pishel、Vladimir Kubyshkin、Dmytro Lesyk、Oleksii Klymenko‐Ulianov、Pavel K. Mykhailiuk

  DOI：10.1002/anie.202311583

  日期：2023.12.18

  1-Azaspiro[3.3]heptanes were synthesized, characterized, and validated biologically as bioisosteres of piperidine. Incorporation of this core into the anesthetic drug bupivacaine instead of the piperidine ring resulted in a patent-free analogue with high activity.

  合成、表征并验证了 1-氮杂螺[3.3]庚烷作为哌啶的生物等排体。将这个核心代替哌啶环掺入麻醉药物布比卡因中，产生了具有高活性的无专利类似物。